Jinhai Medical Technology stock has been on a tear, with the share price up sharply over the past month and quarter. Yet the latest earnings remind you that this is still a loss-making business. The headline from H1 2026 is not the top line. Instead, it is the squeeze on profitability, with Jinhai reporting a net loss of S$4.362 million and basic earnings per share still in the red.

Short term traders have been rewarded by price momentum. Longer term investors now need to weigh those gains against a high price to book multiple and a balance sheet carrying ongoing losses.

Love the recent share price strength in Jinhai Medical Technology but concerned about the ongoing losses and pressure on profitability? Take a look at our list of stocks with stronger balance sheets and established earnings profiles in the list of solid balance sheet and fundamentals stocks (427 results).

H1 2026 Earnings Summary

• Revenue H1 2026 vs. H1 2025: S$34.021 million vs. S$14.529 million (change in top line between periods, exact percentage not stated)
• Net Loss H1 2026 vs. H1 2025: loss of S$4.362 million vs. loss of S$10.253 million (change in reported loss between periods, exact percentage not stated)
• Basic EPS H1 2026 vs. H1 2025: loss of S$0.0008 per share vs. loss of S$0.001983 per share (change in per share loss between periods, exact percentage not stated)
• Trailing 12-month Revenue to H1 2026 vs. to H1 2025: S$65.768 million vs. S$38.833 million (change in revenue over the trailing period, exact percentage not stated)

Tired of scrolling through dense earnings tables and raw figures for Jinhai Medical Technology? For a clear visual read on the company’s balance sheet strength and overall financial picture, see the company report for Jinhai Medical Technology.

Jinhai Medical bullish hopes test against revenue trend

For investors drawn to Jinhai Medical as an emerging healthcare pivot, the latest figures give some support. Revenue for H1 2026 and the trailing 12 months is higher than the prior periods, which points to a larger operating scale than a year ago. The net loss and loss per share have narrowed compared with H1 2025. That combination of higher sales and a smaller loss helps the turnaround narrative, even though the company is still firmly loss making.

Ongoing losses keep Jinhai Medical risk firmly in view

The bearish story around Jinhai Medical also finds backing in these results. The company remains in the red with a S$4.362 million net loss and basic earnings per share still negative. The business mix is complex, and the accounts do not yet show a clear earnings contribution from any one segment that offsets group losses. Recent share price gains over 90 days contrast with continuing losses, so the financials still point to execution risk rather than a settled, profitable medical technology profile.

After a 61.3% annual decline in earnings and a volatile share price, it is worth asking whether Jinhai Medical Technology has deeper structural issues. Review the full risk analysis for Jinhai Medical Technology which shows 2 important warning signs

Stay Ahead Of Your Next Move

If Jinhai Medical Technology is on your radar after its recent share price strength and ongoing losses, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the earnings story develops. Once you decide to take a position, manage your holdings through the Portfolio Command Center so you filter out routine noise and focus on the updates that matter most. Over time, tap into the crowd wisdom inside the Community to see how other investors are thinking about opportunities and risks. By spotting potential catalysts and red flags early, you give yourself a better chance to act with confidence before the wider market reacts.

Seeking Alternatives Beyond Jinhai Medical?

Fresh stock ideas can move from quiet accumulation to full breakout before most investors react. Use these focused screeners while the data is still under the radar for now and act now.

• Target steadier cash flows and balance sheets by scanning a curated list of solid balance sheet and fundamentals stocks (427 results) that can help you sidestep weaker stories and focus on financial resilience.
• Spot potential early leaders in automation by reviewing a hand picked set of 37 robotics and automation stocks that could benefit if robotics momentum keeps building before the crowd notices.
• Position ahead of possible energy grid upgrades by checking a filtered list of 38 power grid technology and infrastructure stocks while these infrastructure ideas are still flying under many investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.